JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257231

Human IFITM3 (Fragilis) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

IFITM3 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and Insertion of the selection cassette in exon1.

View Alternative Names

1 8U, Fragilis, IFITM3, IFM3_HUMAN, IP15, Interferon Inducible Protein 15, Interferon Inducible Protein Homolog, Interferon induced transmembrane protein 3 (1 8U), Interferon inducible, Interferon-induced transmembrane protein 3, Interferon-inducible protein 1-8U

3 Images
Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell lysate (AB257231)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell lysate (AB257231)

Allele-3 : Insertion of the selection cassette in exon1

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell lysate (AB257231)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell lysate (AB257231)

Allele-1 : 1 bp deletion in exon1

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell lysate (AB257231)
  • Sanger seq

Lab

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell lysate (AB257231)

Allele-2 : Insertion of the selection cassette in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and Insertion of the selection cassette in exon1.

Disease

Adenocarcinoma

style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257231-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human IFITM3 knockout HeLa cell lysate", "number":"AB257231-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257231-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
IFITM3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein known as Fragilis also called Interferon-induced transmembrane protein 3 (IFITM3) plays a role in cellular defense mechanisms. Fragilis is approximately 15 kDa in mass. It is commonly expressed in cells of the immune system such as lymphocytes and can also be found in various tissues including the lungs spleen and thymus. This protein includes a chain of functional domains that interact with cellular membranes contributing to its protective roles on the cellular level.
Biological function summary

IFITM3 acts as an antiviral protein that disrupts the life cycle of viruses entering human cells. It is a part of a family of transmembrane proteins that block viral replication by inhibiting the fusion of viral membranes with endosomal membranes. The presence of Fragilis in respiratory epithelial cells is integral to the immune response against viral infections. The protein acts as a barrier to viruses like influenza providing an innate immune defense mechanism.

Pathways

The involvement of IFITM3 is central to the immune signaling pathways specifically the interferon signaling pathway. Upon viral infection interferons upregulate IFITM3 enhancing its antiviral activities. Other proteins like STAT1 and STAT2 mediate this regulation. Additionally IFITM3 aligns with the pathways regulating cell membrane integrity and remodeling highlighting its multi-functional role beyond just antiviral defense.

Research highlights the relevance of IFITM3 in conditions such as influenza and COVID-19. In both cases higher expression levels correlate with better prognosis. For instance variations in IFITM3 expression or genetic mutations can affect susceptibility to severe influenza. Connections with proteins such as MxA and other IFITM proteins can influence these disease processes. These connections make Fragilis a target of interest for understanding and potentially mitigating the severity of viral infections.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB236735

Anti-IFITM2 antibody

Western blot - Anti-IFITM2 antibody (AB236735)

  • 0
  • 0
Primary Antibodies

AB233545

Anti-IFITM1 antibody [EPR22620-12]

BOND RX™ Validated|RabMAb|Recombinant

Western blot - Anti-IFITM1 antibody [EPR22620-12] (AB233545)

  • 0
  • 0
Primary Antibodies

AB109429

Anti-Fragilis antibody [EPR5242]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Fragilis antibody [EPR5242] (AB109429)

  • 4
  • 1
Proteins & Peptides

AB92921

Recombinant Human Fragilis protein

Western blot - Recombinant Human Fragilis protein (AB92921)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com